ClinicalTrials.gg
CompletedNCT05148390GELFIUpdated Feb 21, 2024

Study to Examine Clinical Performance and Safety of Cutimed® Gelling Fiber in Routine Clinical Practice

An observational study in Leg Ulcer, Diabetic Foot Ulcer and Pressure Ulcer, sponsored by BSN Medical GmbH. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-21.

Primary conditionDiabetic FootRegistry: Leg UlcerReclassifiedWhy we changed it
Registry
Leg Ulcer — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetic Foot
Why
  1. The study's listed conditions name Diabetic Foot, a narrower term within Leg Ulcer.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by BSN Medical GmbH · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
36
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Diabetic Foot with a site in Germany — 4 open to participants now, 4 under way, none of them phase 3. Diabetic Foot · Germany.

Started
2022
with 1 other
Observational
8 of 37
1 open now
Registered
30th of 37
by date

Among the 37 studies in Diabetic Foot with a site in Germany, this one is one of 2 that started in 2022, is one of 8 observational ones, and was the 30th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

4 of the 37 studies in Diabetic Foot with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Diabetic Foot with a site in Germany, or all of them as a file.
02

Study summary

This is a post - market study with a wound dressing, a CE-marked medical device available on the european market. The device will be used in routine clinical practice, i.e. within its intended purpose and without any additional invasive or stressing examinations for the patients.

Up to 36 adult patients with wounds suitable to be treated with the medical device and meeting the inclusion/exclusion criteria will be enrolled at two participating German sites.

During 5 on-site visits within 28 days routine weekly dressing changes the Health Care Professional will examine the wound and will perform required wound care and dressing changes. Pictures of the wound with and without dressing will be taken at each visit and used for automatic analysis. The subjects will be asked to rate their general wound pain and the pain perceived during dressing changes. A wound-related quality of life questionnaire will be presented to the subjects twice and the subject and HCP will rate their safisfaction with the product.

Read the detailed description

This Post Market Clinical Follow up (PMCF) study will examine product features of the CE-marked wound dressing after having received market authorization regarding the fulfilment of predefined requirements for the successful management of skin integrity during wound care. The primary purpose of this study is to evaluate clinical safety and performance of the product when used on several wounds in routine wound care without any additional invasive or burdensome methods and within the intended use.

As primary objective the dressing´s absorption performance and its ability to prevent exudate accumulation in the wound will be investigated. Further, device disintegration, need of debridement, wound and skin conditions, treatment related pain, general wound pain, dressing adhesion and quality of life as well as Helath Care professional's (HCP´s) and patient´s satisfaction are considered as secondary outcomes.

In total, 36 eligible subjects will be enrolled at 2 German sites, including 15 % dropouts.

5 on-site visits are to be performed by the subjects in the scope of routine weekly wound care/dressing change visits during 28 days (Day 0, Day7, Day 14, Day21, Day28). The IMD will be applied during each on-site visit including wound care, wound examination/documentation and dressing change according to HCP's judgment and individual circumstances of the wound. Photographic documentation of the wound and the wound with applied dressings will be performed and used for further automatic wound/tissue analyis. General wound pain as well as pain perceived during dressing change will be documented, as well as Wound-related Quality of life as well as Patient's/HCP's satisfaction with the product.

03

Conditions studied

  • Leg Ulcer
  • Diabetic Foot Ulcer
  • Pressure Ulcer
  • Surgical Wound
  • Abrasion
  • Laceration
  • Burn, Partial Thickness
  • Oncology Wound
04

In context

Diabetic Foot Reclassified

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

This study's enrollment of 36 is below the median of 100 across 191 observational studies indexed under Diabetic Foot.

Browse Diabetic Foot studies →

Lead sponsor

BSN Medical GmbH is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Compared within Diabetic Foot, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leg Ulcer. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Representativeness of the investigation population is assumed to be high in relation to the target population since this is a PMCF study, where the IMD will be used within the intended purpose including the intended patient population. Therefore, the IMD will be tested by the population for whom it is in fact intended for once placed on the market among other intended users. Inclusion and exclusion criteria are aligned with the product´s intended purpose.

No vulnerable subjects such as children, pregnant women, or sponsors or manufacturers staff will participate in this study guaranteed by specific inclusion and exclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • mentally and physically able to participate in study
  • written to participate in the study
  • Diagnosed wound indicated for treatment with Cutimed® Gelling Fiber for 4 weeks (except for internal body cavities and closed wounds)
  • Subjects with more than one ulcer are eligible for inclusion, however only one ulcer per subject will be included in the study.

Exclusion criteria

Exclusion Criteria:

  • Sensitivity to or allergic reaction to the dressing or its components
  • Participation in any other clinical study investigating drugs or medical devices
  • Subjects presenting with wounds including internal body cavities or closed wounds
  • Alcohol and drug addiction
  • Pregnant or breast-feeding subjects
  • Underlying diseases are not treated according to respective country-specific guidelines
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
36 participants (actual)
Patient registry
No

Interventions

  • DeviceCutimed® Gelling Fiber

    application of dressing

07

What researchers measure

Primary outcomes

  1. Exudate absorption by IMD ('yes', 'no')

    Percentage of subjects with exudate absorbed by the IMD per visit

    Time frame: day 7

  2. Exudate absorption by IMD ('yes', 'no')

    Percentage of subjects with exudate absorbed by the IMD per visit

    Time frame: day 14

  3. Exudate absorption by IMD ('yes', 'no')

    Percentage of subjects with exudate absorbed by the IMD per visit

    Time frame: day 21

  4. Exudate absorption by IMD ('yes', 'no')

    Percentage of subjects with exudate absorbed by the IMD per visit

    Time frame: day 28

  5. Exudate accumulation in the wound by IMD ( 'no', 'minimal amount', 'medium amount', 'high amount')

    Percentage of subjects with remaining exudate in wound per amount and visit

    Time frame: day 7

  6. Exudate accumulation in the wound by IMD ( 'no', 'minimal amount', 'medium amount', 'high amount')

    Percentage of subjects with remaining exudate in wound per amount and visit

    Time frame: day 14

  7. Exudate accumulation in the wound by IMD ( 'no', 'minimal amount', 'medium amount', 'high amount')

    Percentage of subjects with remaining exudate in wound per amount and visit

    Time frame: day 21

  8. Exudate accumulation in the wound by IMD ( 'no', 'minimal amount', 'medium amount', 'high amount')

    Percentage of subjects with remaining exudate in wound per amount and visit

    Time frame: day 28

Secondary outcomes

  1. Changes in need for debridement

    Percentage of subjects with need for debridement per visit

    Time frame: Throughout days 0, 7, 14, 21 and 28

  2. Changes in debridement ease

    Percentage of subjects per debridement ease ('easy', 'moderate', 'heavy', 'not applicable') per visit

    Time frame: Throughout days 0, 7, 14, 21 and 28

  3. Changes in wound margin condition

    Percentage of subjects per wound margin condition('intact', 'macerated', 'redness', 'ragged') per visit

    Time frame: Throughout days 0, 7, 14, 21 and 28

  4. Changes in peri-wound skin condition

    Percentage of subjects per peri-wound skin condition ('intact', 'macerated', 'redness', 'dry/flaky', 'edematous' ,'weeping') per visit

    Time frame: Throughout days 0, 7, 14, 21 and 28

  5. Changes in wound tissue type

    Percentage of subjects per wound tissue type ('epithelialization tissue', 'granulation tissue', 'slough', 'eschar/necrotic tissue', 'other') per visit

    Time frame: Throughout days 0, 7, 14, 21 and 28

  6. Ease of application

    Percentage of subjects per ease of application ('very easy', 'easy', 'difficult', 'very difficult') per visit

    Time frame: Throughout days 0, 7, 14, 21 and 28

  7. Conformability during application

    Percentage of subjects per conformability ('very good', 'good', 'poor', 'very poor') per visit

    Time frame: Throughout days 0, 7, 14, 21 and 28

  8. Ease of removal

    Percentage of subjects per ease of removal ('very easy', 'easy', 'difficult', 'very difficult') per visit

    Time frame: Throughout days 7, 14, 21 and 28

  9. Dressing adherence on removal

    Percentage of subjects per adherence ('none', 'minor', 'moderate', 'marked') per visit

    Time frame: Throughout days 7, 14, 21 and 28

  10. Pain on removal

    Mean pain perceived by subject using a pain ruler (scale 0-10) per visit

    Time frame: Throughout days 7, 14, 21 and 28

  11. Changes in wound-pain

    Mean pain perceived by subject using a pain ruler (scale 0-10) per visit

    Time frame: Throughout days 7, 14, 21 and 28

  12. Changes in Wound-quality of life Wound-QoL

    percentage change in Wound-QoL total scores and subscale scores ('body', 'psyche', 'everyday life' and standalone item) between both visits

    Time frame: Day 0 and Day 28

  13. HCP Overall satisfaction

    Percentage per HCP overall satisfaction category ('Very good', 'Good', 'Satisfactory', 'Sufficient', 'Insufficient') for final visit

    Time frame: day 28

  14. Subject Overall satisfaction

    Percent of patient overall satisfaction category ('Very good', 'Good', 'Satisfactory', 'Sufficient', 'Insufficient') for all patients at visit 5

    Time frame: day 28

  15. Incidence of adverse events related to IMD

    Total occurence of IMD related adverse events

    Time frame: Throughout days 0, 7, 14, 21 and 28

  16. Incidence of device disintegration (removability in one piece)

    Total occurence of IMD disintegration during removal

    Time frame: Throughout days 0, 7, 14, 21 and 28

08

Study locations

1 site
  • Christliches Klinikum Melle GmbH, Unfallchirurgie
    Melle, 49324, Germany
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Jul 2023, 15 months.

Of 90 observational studies under Diabetic Foot, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 59. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2021
First posted
Dec 8, 2021
StartActual
Apr 24, 2022
Primary completionActual
Jul 26, 2023
CompletionActual
Jul 26, 2023
Last update
Feb 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05148390
Lead sponsor
BSN Medical GmbH
Responsible party
Sponsor
First posted
Dec 8, 2021
Start date
Apr 24, 2022
Primary completion
Jul 26, 2023
Completion
Jul 26, 2023
Last update
Feb 21, 2024

Study contacts

Arne Böhling, Dr.
study director · BSN Medical GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion